OverviewSuggest Edit

Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases. It is primarily focused on developing medicines to treat multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The company also manufactures and commercializes biosimilars of advanced biologics.
TypePublic
Founded1978
HQCambridge, MA, US
Websitebiogen.com
Employee Ratings4.2
Overall CultureA-

Latest Updates

Employees (est.) (Dec 2019)7,400(-5%)
Job Openings282
Revenue (FY, 2020)$13.4 B(-6%)
Share Price (Apr 2021)$277.9
Cybersecurity ratingCMore

Key People/Management at Biogen

Michel Vounatsos

Michel Vounatsos

Chief Executive Officer and Director
Stelios Papadopoulos

Stelios Papadopoulos

Chairman of the Board
Alisha Alaimo

Alisha Alaimo

President, Biogen U.S. Organization
Johanna Friedl-Naderer

Johanna Friedl-Naderer

President, Europe, Canada & Partner Markets
Alexander J. Denner

Alexander J. Denner

Director and Chair, Corporate Governance Committee
Rachid Izzar

Rachid Izzar

President, Biogen Intercontinental Region
Show more

Biogen Office Locations

Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 34 other locations
Cambridge, MA, US (HQ)
225 Binney St
Morrisville, NC, US
5000 Davis Dr
Waltham, MA, US
203 Crescent St #303
Washington, DC, US
601 Pennsylvania Ave NW #720
Weston, MA, US
133 Boston Post Rd
Vicente López, AR
7th Floor, Av. del Libertador 350
Show all (39)

Biogen Financials and Metrics

Biogen Revenue

Embed Graph
View revenue for all periods
Biogen's revenue was reported to be $13.44 b in FY, 2020
USD

Revenue (FY, 2020)

13.4b

Gross profit (FY, 2020)

11.6b

Gross profit margin (FY, 2020), %

86.6%

Net income (FY, 2020)

4.1b

EBIT (FY, 2020)

4.6b

Market capitalization (5-Apr-2021)

42.3b

Closing stock price (5-Apr-2021)

277.9

Cash (31-Dec-2020)

1.3b

EV

48.4b
Biogen's current market capitalization is $42.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

12.3b13.5b14.4b13.4b

Revenue growth, %

10%7%

Cost of goods sold

1.6b1.8b2.0b1.8b

Gross profit

10.6b11.6b12.4b11.6b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

2.8b3.1b3.1b3.1b3.4b3.4b3.5b3.6b3.6b3.5b3.7b3.4b

Cost of goods sold

384.6m366.2m370.0m446.0m421.0m460.8m602.0m476.3m430.0m454.3m411.1m449.1m

Gross profit

2.4b2.7b2.7b2.7b2.9b3.0b2.9b3.1b3.2b3.1b3.3b2.9b

Gross profit Margin, %

86%88%88%86%87%87%83%87%88%87%89%87%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

1.6b1.2b2.9b1.3b

Accounts Receivable

1.8b2.0b1.9b1.9b

Inventories

902.7m929.9m804.2m

Current Assets

7.9b7.6b8.4b6.9b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

924.0m1.2b1.5b4.1b1.3b2.4b2.2b1.7b2.3b2.6b2.4b2.2b

Accounts Receivable

1.5b1.6b1.6b1.9b2.0b2.0b2.1b2.0b1.9b2.1b2.1b2.0b

Inventories

921.6m936.5m1.0b890.8m931.7m916.6m770.2m776.7m751.8m858.8m952.7m1.0b

Current Assets

6.9b7.1b7.6b10.2b7.4b8.7b8.9b7.9b8.4b8.0b8.5b7.8b
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

2.7b4.5b5.9b4.1b

Depreciation and Amortization

1.1b1.0b680.6m457.2m

Inventories

(94.5m)(52.1m)(19.2m)(316.3m)

Cash From Operating Activities

4.6b6.2b7.1b4.2b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

747.5m1.6b2.8b1.2b2.1b3.5b1.4b2.9b4.4b1.4b3.0b3.7b

Depreciation and Amortization

512.0m814.6m992.0m168.9m340.4m686.9m121.1m238.1m567.6m119.9m232.8m366.8m

Inventories

(46.2m)(85.3m)(170.3m)(2.6m)(40.1m)(31.9m)(129.0m)(108.7m)(47.3m)(62.2m)(188.2m)(270.6m)

Cash From Operating Activities

235.2m1.4b3.0b1.5b2.6b4.3b1.5b3.4b5.1b1.5b3.4b4.6b
USDQ1, 2017

Debt/Equity

0.6 x

Debt/Assets

0.3 x

Financial Leverage

1.8 x
Show all financial metrics

Biogen Operating Metrics

FY, 2016FY, 2017FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020Q3, 2020

Phase I Trials Products

447689991113

Phase I/II Trials Products

1

Phase II Trials Products

1012131312121110109

Phase III Trials Products

2343556666
Show all operating metrics

Biogen Acquisitions / Subsidiaries

Company NameDateDeal Size
Nightstar TherapeuticsMarch 04, 2019$800 m
AliveGenJuly 25, 2018$27.5 m
Karyopharm TherapeuticsJanuary 25, 2018$10 m
Remedy PharmaceuticalsMay 18, 2017$120 m
Convergence PharmaceuticalsFebruary 14, 2014$675 m
StromedixFebruary 14, 2014$75 m
TysabriFebruary 28, 2013
Syntonix PharmaceuticalsJanuary 04, 2007$120 m
FumapharmMay 31, 2006
Conforma TherapeuticsMay 03, 2006$150 m
Show more

Biogen Revenue Breakdown

Embed Graph

Biogen revenue breakdown by business segment: 15.9% from Anti-CD20 Therapeutic Programs, 79.1% from Product Revenues and 4.9% from Other

Human Capital Metrics

Embed Graph
Show all human capital metrics

Biogen Cybersecurity Score

Cybersecurity ratingPremium dataset

C

76/100

SecurityScorecard logo

Biogen Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Biogen Online and Social Media Presence

Embed Graph

Biogen Company Culture

  • Overall Culture

    A-

    78/100

  • CEO Rating

    B

    72/100

  • Compensation

    A+

    88/100

  • Diversity

    A

    80/100

Learn more on Comparably

Biogen News and Updates

Outlook on the Antisense Oligonucleotide Therapeutics Global Market to 2030 - Featuring Biogen, Bio-Path Holdings and Sarepta Therapeutics Among Others

Dublin, April 01, 2021 (GLOBE NEWSWIRE) -- The "Antisense Oligonucleotide Therapeutics Market by Target Indication, Type of Therapy, Type of Molecule Type of Generation and Key Geographies: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Worldwide Neuralgia Treatment Industry to 2027 - Players Include Allergan, GlaxoSmithKline & Biogen Among Others

Dublin, March 19, 2021 (GLOBE NEWSWIRE) -- The "Neuralgia Treatment Market Size, Share & Trends Analysis Report, By Treatment; By End-Use; By Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global neuralgia treatment market size is pred…

Insights on the Alzheimer's Disease Drugs Global Market to 2027 - Featuring Allergen, Biogen and Genentech Among Others

DUBLIN, March 12, 2021 /PRNewswire/ -- The "Alzheimer's Disease Drugs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19 crisis, the global market for Alzheimers Disease Drugs estimated at US$ 5.9 Billion in the year 2020,...

Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced its plans to build a new gene therapy manufacturing facility at its Research Triangle Park (RTP) manufacturing campuses in North Carolina to support its growing gene therapy pipeline across multiple the…

Biopharma Closely Watching Biden’s Pick For The Next FDA Commissioner – With Biogen Having The Most At Stake

If approved, biopharmaceutical critics will accuse the F.D.A. of being too closely aligned with industry. If rejected, the F.D.A will be attacked by patients and advocacy groups as preventing access to a much needed new medicine.

Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program

CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Life Science Cares Boston and the Biogen Foundation have teamed up as inaugural sponsors of Food For Free’s new Just Eats Grocery Box program, a $170,000 effort to reduce food insecurity for 3,000 area families, starting this month. To launch Jus…
Show more

Biogen Blogs

Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint

Statistically significant reduction in tremor score compared to placebo at Day 29 in adults with essential tremor SAGE-324 demonstrated a 36% reduction in upper limb tremor amplitude from baseline at Day 29 in the total studied population; in a more severe population (baseline TETRAS Upper Limb

Biogen Announces Two New Nominees for Election to Board of Directors

Nominees bring diverse business and public health experience key to Biogen’s mission to pioneer and lead in neuroscience Company thanks Director Robert W. Pangia as he retires from the Board CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.

Biogen to Report First Quarter 2021 Financial Results April 22, 2021

Cambridge, Mass.— Biogen Inc . (Nasdaq:BIIB) today announced it will report first quarter 2021 financial results Thursday, April 22, 2021, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.

Biogen to Participate in the Stifel 3rd Annual CNS Day

Biogen to Participate in the Stifel 3rd Annual CNS Day Ray.Beron@west.com Mon, 03/22/2021 - 12:51 Biogen to Participate in the Stifel 3rd Annual CNS Day March 22, 2021 at 4:06 PM EDT This release is a backfill from a News Wire Investor Re…

Biogen to Webcast Aducanumab Presentations from AD/PD 2021 Virtual Conference on March 9-13, 2021

Cambridge, Mass. – Biogen (Nasdaq: BIIB) today announced it will host webcasts of its pre-recorded presentations and live discussions related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming AD/PDTM 2021 Virtual Conference.  AD/PD Webcast Schedule Details: Wednesday,

Biogen to Participate in the Cowen 41st Annual Health Care Conference

Biogen to Participate in the Cowen 41st Annual Health Care Conference joseibrahim.de… Mon, 02/22/2021 - 10:23 Biogen to Participate in the Cowen 41st Annual Health Care Conference February 22, 2021 at 4:06 PM EST This release is a backfill from a News Wire …
Show more

Biogen Frequently Asked Questions

  • When was Biogen founded?

    Biogen was founded in 1978.

  • Who are Biogen key executives?

    Biogen's key executives are Michel Vounatsos, Stelios Papadopoulos and Alisha Alaimo.

  • How many employees does Biogen have?

    Biogen has 7,400 employees.

  • What is Biogen revenue?

    Latest Biogen annual revenue is $13.4 b.

  • What is Biogen revenue per employee?

    Latest Biogen revenue per employee is $1.8 m.

  • Who are Biogen competitors?

    Competitors of Biogen include Cassava Sciences, Covance and Sanofi Genzyme.

  • Where is Biogen headquarters?

    Biogen headquarters is located at 225 Binney St, Cambridge.

  • Where are Biogen offices?

    Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 34 other locations.

  • How many offices does Biogen have?

    Biogen has 39 offices.